These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1279288)

  • 61. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
    Fulton B; Wagstaff AJ; Sorkin EM
    Drugs; 1995 Feb; 49(2):295-320. PubMed ID: 7537194
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
    Hoogerbrugge N; de Groot E; de Heide LH; de Ridder MA; Birkenhägeri JC; Stijnen T; Jansen H
    Neth J Med; 2002 Oct; 60(9):354-61. PubMed ID: 12572707
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Doxazosin therapy in the treatment of diabetic hypertension.
    Feher MD
    Am Heart J; 1991 Apr; 121(4 Pt 2):1294-301. PubMed ID: 1826186
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies.
    Brude IR; Drevon CA; Viken K; Arnstad JE; Valnes KN; Nenseter MS
    Biochem Pharmacol; 1999 Jul; 58(1):183-91. PubMed ID: 10403533
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].
    Sznajderman M; Chotkowska E; Peczkowska M; Sawicki M; Janaszek-Sitkowska H; Wiernikowska-Wegorek I; Galewicz A; Cybulska I
    Kardiol Pol; 1993 Feb; 38(2):107-11. PubMed ID: 8230980
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of doxazosin GITS in hypertensive renal transplant patients: comparison of 8 and 4 mg.
    Oliveras A; Hurtado S; Vázquez S; Puig JM; Lloveras J
    Transplant Proc; 2003 Aug; 35(5):1732-5. PubMed ID: 12962775
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin : results from the HALT study.
    Kario K; Schwartz JE; Pickering TG
    Hypertension; 2000 Mar; 35(3):787-94. PubMed ID: 10720596
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
    Baez MA; Garg DC; Jallad NS; Weidler DJ
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme].
    Fernández Pinilla C; Luque Otero M; Martell Claros N; Alcázar de la Osa JM; Rodicio Díaz JL; Ruilope Urioste LM
    Med Clin (Barc); 1993 Jun; 101(5):168-71. PubMed ID: 8332009
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
    Lazebnik LB; Melichenko SB; Serebrov AN
    Ter Arkh; 1998; 70(2):50-4. PubMed ID: 9551574
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
    Kaplan SA; Meade-D'Alisera P; Quiñones S; Soldo KA
    Urology; 1995 Oct; 46(4):512-7. PubMed ID: 7571220
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system.
    Guzik P; Wykretowicz A; Krauze T; Piskorski J; Adamska K; Milewska A; Wesseling KH; Wysocki H
    Hypertens Res; 2008 Mar; 31(3):443-53. PubMed ID: 18497463
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
    Ahaneku JE; Taylor GO; Agbedana EO; Walker O; Salako LA
    J Pak Med Assoc; 1994 Jul; 44(7):166-9. PubMed ID: 7933456
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL.
    Kinoshita M; Shimazu N; Fujita M; Fujimaki Y; Kojima K; Mikuni Y; Horie E; Teramoto T
    Am J Hypertens; 2001 Mar; 14(3):267-70. PubMed ID: 11281239
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
    Pool JL
    Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The cost-benefit approach to pricing new medicines: doxazosin versus beta-blocker treatment in Sweden.
    Lindgren B
    Am Heart J; 1990 Mar; 119(3 Pt 2):748-53. PubMed ID: 1968701
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension.
    Toth K; Nemes J; Czopf L; Kapronczay P; Kesmarky G; Juricskay I
    Clin Hemorheol Microcirc; 1999; 20(1):57-61. PubMed ID: 11185685
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):69S-75S. PubMed ID: 2939870
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
    Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
    Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.